Haleon plc reports consumer health developments across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's news commonly covers product launches and brand activity for names such as Sensodyne, parodontax, Centrum, Advil, TUMS, Theraflu, Voltaren, Polident and Panadol.
Recurring updates include oral-care innovation, multivitamin research, consumer marketing campaigns, regional growth initiatives, manufacturing investment, and leadership changes within the U.S. and other markets. As a foreign issuer with American depositary shares traded under HLN, company announcements may also address parent-company reporting, governance and capital-market communications.
Haleon has launched Eroxon®, the first FDA-cleared over-the-counter gel for erectile dysfunction (ED) in the U.S. Available for pre-order on Amazon and in major retailers by October 2024, Eroxon® is clinically proven to help men achieve erections within 10 minutes. This fast-acting treatment addresses a significant unmet need, as existing prescription solutions can take up to an hour to work.
Clinical studies demonstrate Eroxon®'s safety and efficacy for men with ED. The gel stimulates nerve endings in the penis to aid in achieving and maintaining erections. Haleon aims to make this accessible treatment available to millions of American men affected by ED, emphasizing the importance of sexual health in overall wellness.
Dr. Reddy's Laboratories announced the acquisition of Haleon's Nicotinell and related NRT brands for GBP 500 million. The acquisition includes Nicotinell's global portfolio, comprising Nicabate, Thrive, and Habitrol, across Europe, Asia, and Latin America. The deal features an upfront payment of GBP 458 million and performance-based payments of up to GBP 42 million. Nicotinell, the second-largest NRT brand globally, generated GBP 217 million in revenue in CY'23. Dr. Reddy's aims to expand its OTC business and strengthen its global consumer healthcare presence. The transaction is expected to close in early Q4 2024.
Yellow Wood Partners, a Boston-based private equity firm, announced that its portfolio company, Suave Brands Company, has completed the acquisition of the ChapStick brand from Haleon (LSE / NYSE: HLN). This acquisition also makes Haleon a shareholder in Suave Brands Company. The CEO of Suave Brands, Daniel Alter, stated that the addition of ChapStick fits their growth strategy and enhances their position in the North American beauty and personal care market. Suave Brands, known for offering affordable personal care products, now boasts annual retail sales of around $800 million. Yellow Wood Partners highlighted the strategic value of combining ChapStick with Suave, expanding product capabilities, and leveraging Suave's market presence. The acquisition aligns with Yellow Wood Partners' approach to value-creating acquisitions and organic growth strategies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.